The Silent Plague: Regulation of Latent Tuberculosis Infections

Behinaein, Parnia; Cirillo, Jeffrey D.

doi:10.1007/978-3-030-25381-3_2

Cited by 2 publications

(1 citation statement)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such circumstances may arise if the bacteria are not fully eradicated during the treatment. The remaining few that are still present in the body can maintain themselves in a latent phase which later leads to relapse of the disease after a certain amount of time has passed (Behinaein and Cirillo 2019;WHO 2020). These contributing factors also help us to comprehend the long duration of TB treatments mandatory for curing active TB infections.…”

Section: Challenges In the Treatment Of Tuberculosismentioning

confidence: 99%

Use of Nanotechnology to Mitigate Tuberculosis

2023

IJAB

View full text Add to dashboard Cite

Tuberculosis is a disastrous malady spreading exponentially throughout the world. TB has been long identified as a threat to global health by several international bodies but this threat was amplified upon the identification of multi-drug-resistant germs of TB. Such a scenario arose from several factors regarding TB. Some important factors in this aspect include lack of awareness as TB is prevalent in low-income, loweducation countries and exhaustive treatment regimens for TB. Similarly, the adverse effects of drugs are also a factor leading to hampering proper dose implementation. Liver damage caused by anti-TB drugs often leads to a pause in TB medication in turn contributing to increased antibiotic resistance to etiologic agents of TB. Such problems can be easily overcome by developing antibiotic alternatives that can battle antibiotic resistance while reducing the length and adverse effects of the TB medication. Such an option regarding antibiotic alternatives is the use of nanotechnology and nanomaterials. These substances can help us battle anti-microbial resistance by bypassing the defense mechanism of TB bacteria while simultaneously preventing side effects of the drugs through reduced doses.

show abstract

Section: Challenges In the Treatment Of Tuberculosismentioning

confidence: 99%

Use of Nanotechnology to Mitigate Tuberculosis

2023

IJAB

View full text Add to dashboard Cite

show abstract

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial‐loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment.

show abstract

The Silent Plague: Regulation of Latent Tuberculosis Infections

Cited by 2 publications

References 112 publications

Use of Nanotechnology to Mitigate Tuberculosis

Use of Nanotechnology to Mitigate Tuberculosis

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Contact Info

Product

Resources

About